Your browser doesn't support javascript.
loading
Benchmarking mismatch repair testing for patients with cancer receiving immunotherapy.
Bou Farhat, Elias; Adib, Elio; Daou, Melissa; Naqash, Abdul Rafeh; Matulonis, Ursula; Ng, Kimmie; Kwiatkowski, David J; Sholl, Lynette M; Nassar, Amin H.
Afiliación
  • Bou Farhat E; Brigham and Women's Hospital, Boston, MA, USA.
  • Adib E; Brigham and Women's Hospital, Boston, MA, USA.
  • Daou M; Brigham and Women's Hospital, Boston, MA, USA.
  • Naqash AR; University of Oklahoma, Stephenson Cancer Center, Oklahoma City, OK, USA.
  • Matulonis U; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Ng K; Dana-Farber Cancer Institute, Boston, MA, USA.
  • Kwiatkowski DJ; Brigham and Women's Hospital, Boston, MA, USA.
  • Sholl LM; Brigham and Women's Hospital, Boston, MA, USA.
  • Nassar AH; Brigham and Women's Hospital, Boston, MA, USA; Yale Cancer Center, New Haven, CT, USA. Electronic address: amin.nassar@yale.edu.
Cancer Cell ; 42(1): 6-7, 2024 01 08.
Article en En | MEDLINE | ID: mdl-38157866
ABSTRACT
Immunohistochemistry (IHC) is currently the first-line test for mismatch repair deficiency (MMR-D). Bou Farhat et al. show that mismatch repair (MMR) mutation signature by next-generation sequencing is a highly sensitive assay capable of detecting MMR-D cases that are missed in 1% and 5% of patients with MMR-D colorectal cancer (CRC) and endometrial cancer (EC), respectively. Patients with MMR-D tumors missed by IHC have similar clinical outcomes to patients with MMR-D by both IHC and mutation signature.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Neoplásicos Hereditarios / Neoplasias Colorrectales / Neoplasias Endometriales Límite: Female / Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Síndromes Neoplásicos Hereditarios / Neoplasias Colorrectales / Neoplasias Endometriales Límite: Female / Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos